Paper31329461
Central Nervous System Delivery and Biodistribution Analysis of an Antibody-Enzyme Fusion for the Treatment of Lafora Disease.
Austin GL and 11 others. Mol Pharm, 2019. Cited by 22 papers, by iCite.
Cite this record
ConductScience Library. Central Nervous System Delivery and Biodistribution Analysis of an Antibody-Enzyme Fusion for the Treatment of Lafora Disease. Papers, record 31329461. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31329461
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Brain | Major topic |
| Drug Delivery Systems | Major topic |
| Immunoglobulin Fab Fragments | Major topic |
| Lafora Disease | Major topic |
| Pancreatic alpha-Amylases | Major topic |
| Animals | |
| Artificial Gene Fusion | |
| Disease Models, Animal | |
| Drug Carriers | |
| Enzyme-Linked Immunosorbent Assay | |
| Glucans | |
| HEK293 Cells | |
| Humans | |
| Mice | |
| Mice, Knockout | |
| Plasmids | |
| Protein Tyrosine Phosphatases, Non-Receptor | |
| Tissue Distribution | |
| Treatment Outcome |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P01 NS097197 | NINDS NIH HHS | United States | P01NS097197 | PubMed and NIH | NIH RePORTER |
| P30 CA177558 | NCI NIH HHS | United States | P30CA177558 | PubMed and NIH | NIH RePORTER |
| R01 NS070899 | NINDS NIH HHS | United States | R01NS070899 | PubMed and NIH | NIH RePORTER |
| TL1 TR001997 | NCATS NIH HHS | United States | TL1TR001997 | PubMed | NIH RePORTER |
References46
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27702709 | Lafora disease. | Epileptic Disord | 2016 | https://conductscience.org/library/papers/27702709 | PubMed |
| 2 | 17525162 | Intranuclear protein transduction through a nucleoside salvage pathway. | J Biol Chem | 2007 | https://conductscience.org/library/papers/17525162 | PubMed |
| 3 | 25449807 | Probing the extracellular diffusion of antibodies in brain using in vivo integrative optical imaging and ex vivo fluorescence imaging. | J Control Release | 2015 | https://conductscience.org/library/papers/25449807 | PubMed |
| 4 | 17952067 | Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. | Nat Neurosci | 2007 | https://conductscience.org/library/papers/17952067 | PubMed |
| 5 | 23026637 | Fusion protein linkers: property, design and functionality. | Adv Drug Deliv Rev | 2013 | https://conductscience.org/library/papers/23026637 | PubMed |
| 6 | 24452334 | Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease. | Hum Mol Genet | 2014 | https://conductscience.org/library/papers/24452334 | PubMed |
| 7 | 28154884 | Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease. | J Mol Med (Berl) | 2017 | https://conductscience.org/library/papers/28154884 | PubMed |
| 8 | 23307925 | Enzyme replacement therapy rescues weakness and improves muscle pathology in mice with X-linked myotubular myopathy. | Hum Mol Genet | 2013 | https://conductscience.org/library/papers/23307925 | PubMed |
| 9 | 29483193 | Lafora disease offers a unique window into neuronal glycogen metabolism. | J Biol Chem | 2018 | https://conductscience.org/library/papers/29483193 | PubMed |
| 10 | 29023798 | Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery. | J Physiol | 2018 | https://conductscience.org/library/papers/29023798 | PubMed |
| 11 | 29475602 | The 3rd International Lafora Epilepsy Workshop: Evidence for a cure. | Epilepsy Behav | 2018 | https://conductscience.org/library/papers/29475602 | PubMed |
| 12 | 22364389 | Laforin, a protein with many faces: glucan phosphatase, adapter protein, et alii. | FEBS J | 2013 | https://conductscience.org/library/papers/22364389 | PubMed |
| 13 | 30265523 | Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. | Bioconjug Chem | 2018 | https://conductscience.org/library/papers/30265523 | PubMed |
| 14 | 14237775 | LAFORA'S DISEASE. DISTINCT CLINICO-PATHOLOGIC FORM OF UNVERRICHT'S SYNDROME. | Arch Neurol | 1965 | https://conductscience.org/library/papers/14237775 | PubMed |
| 15 | 4104134 | Studies in myoclonus epilepsy. 3. The effects of amylolytic enzymes on the ultrastructure of Lafora bodies. | J Histochem Cytochem | 1971 | https://conductscience.org/library/papers/4104134 | PubMed |
| 16 | 21552327 | PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. | PLoS Genet | 2011 | https://conductscience.org/library/papers/21552327 | PubMed |
| 17 | 4164450 | Isolation and characterization of Lafora bodies in two cases of myoclonus epilepsy. | J Neuropathol Exp Neurol | 1967 | https://conductscience.org/library/papers/4164450 | PubMed |
| 18 | 20036416 | Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins. | J Allergy Clin Immunol | 2010 | https://conductscience.org/library/papers/20036416 | PubMed |
| 19 | 4175641 | Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases. | Arch Neurol | 1968 | https://conductscience.org/library/papers/4175641 | PubMed |
| 20 | 29793829 | Best practices for the use of intracerebroventricular drug delivery devices. | Mol Genet Metab | 2018 | https://conductscience.org/library/papers/29793829 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41898855 | SINEUP-Mediated Overexpression of Endogenous α-Amylase as a Therapeutic Approach in Lafora Disease. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/41898855 | PubMed |
| 41825228 | Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation. | Neurotherapeutics | 2026 | https://conductscience.org/library/papers/41825228 | PubMed |
| 41465357 | Adeno-Associated Virus-Based Gene Therapy for Lafora Disease in Epm2b-Deficient Mice. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41465357 | PubMed |
| 41326286 | New therapeutic strategies for Lafora disease: Evaluation of the safety, efficacy, pharmacokinetics and metabolomic profile of intravenous VAL-1221 treatment. | Neurotherapeutics | 2026 | https://conductscience.org/library/papers/41326286 | PubMed |
| 40876194 | The 9th annual Lafora science symposium: a rare epilepsy community makes progress towards clinical readiness. | Epilepsy Behav | 2025 | https://conductscience.org/library/papers/40876194 | PubMed |
| 40711973 | Recombinant human alpha-N-acetylglucosamine-6-sulfatase delivered to Sanfilippo D mice with repeated intracerebroventricular injections corrects CNS pathology. | PLoS One | 2025 | https://conductscience.org/library/papers/40711973 | PubMed |
| 39277505 | Neurological glycogen storage diseases and emerging therapeutics. | Neurotherapeutics | 2024 | https://conductscience.org/library/papers/39277505 | PubMed |
| 38137127 | Lafora Disease: A Case Report and Evolving Treatment Advancements. | Brain Sci | 2023 | https://conductscience.org/library/papers/38137127 | PubMed |
| 37700152 | Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model. | Neurotherapeutics | 2023 | https://conductscience.org/library/papers/37700152 | PubMed |
| 37554056 | The multifaceted roles of the brain glycogen. | J Neurochem | 2024 | https://conductscience.org/library/papers/37554056 | PubMed |
| 36059248 | In situ mass spectrometry imaging reveals heterogeneous glycogen stores in human normal and cancerous tissues. | EMBO Mol Med | 2022 | https://conductscience.org/library/papers/36059248 | PubMed |
| 35835895 | Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model. | Mol Neurobiol | 2022 | https://conductscience.org/library/papers/35835895 | PubMed |
| 35743315 | Trehalose Treatment in Zebrafish Model of Lafora Disease. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35743315 | PubMed |
| 34755096 | An empirical pipeline for personalized diagnosis of Lafora disease mutations. | iScience | 2021 | https://conductscience.org/library/papers/34755096 | PubMed |
| 34301405 | Lafora disease: Current biology and therapeutic approaches. | Rev Neurol (Paris) | 2022 | https://conductscience.org/library/papers/34301405 | PubMed |
| 34043942 | Brain glycogen serves as a critical glucosamine cache required for protein glycosylation. | Cell Metab | 2021 | https://conductscience.org/library/papers/34043942 | PubMed |
| 33960213 | A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes. | Nanomedicine (Lond) | 2021 | https://conductscience.org/library/papers/33960213 | PubMed |
| 33946009 | The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure. | Epilepsy Behav | 2021 | https://conductscience.org/library/papers/33946009 | PubMed |
| 33602551 | 251st ENMC international workshop: Polyglucosan storage myopathies 13-15 December 2019, Hoofddorp, the Netherlands. | Neuromuscul Disord | 2021 | https://conductscience.org/library/papers/33602551 | PubMed |
| 31932179 | The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic. | Epilepsy Behav | 2020 | https://conductscience.org/library/papers/31932179 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AMY2A | 279 | PubTator's text mining | https://conductscience.org/library/genes/279 | NCBI Gene |
| CBLL2 | 158506 | PubTator's text mining | https://conductscience.org/library/genes/158506 | NCBI Gene |
| EPM2A | 7957 | PubTator's text mining | https://conductscience.org/library/genes/7957 | NCBI Gene |
| NHLRC1 | 378884 | PubTator's text mining | https://conductscience.org/library/genes/378884 | NCBI Gene |
| SUCO | 51430 | PubTator's text mining | https://conductscience.org/library/genes/51430 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31329461
GET https://conductscience.org/api/papers/v1/31329461/references?page=2